Book contents
- Behavioural Economics and Policy for Pandemics
- Behavioural Economics and Policy for Pandemics
- Copyright page
- Epigraph
- Contents
- Contributors
- Preface
- Acknowledgements
- 1 Behavioural Economics and Policy for Pandemics
- Part I Evidence from Experiments and Behavioural Insights
- 2 What Have We Learned from Behavioural Economics for the COVID-19 Response?
- 3 Adaptation, COVID-19, and Climate Change
- 4 Risk-Taking, Risk Perception, and Risk Compensation in Times of COVID-19
- 5 A False Sense of Security?
- 6 Preparing for the Next Pandemic
- 7 Human Challenge Trials for Research on COVID-19 and Beyond
- 8 Do the Public Support ‘Hard’ or ‘Soft’ Public Policies?
- 9 One Size Does Not Fit All
- 10 Psychological and Behavioural Aspects of the COVID-19 Pandemic
- 11 Behavioural Science and the Irish COVID-19 Response
- 12 On the Use of Behavioural Science in a Pandemic
- 13 Behavioural Public Health?
- Part II Health Behaviours and Policies during Covid-19
- Index
- References
7 - Human Challenge Trials for Research on COVID-19 and Beyond
The Case of 1Day Sooner
from Part I - Evidence from Experiments and Behavioural Insights
Published online by Cambridge University Press: 31 January 2025
Book contents
- Behavioural Economics and Policy for Pandemics
- Behavioural Economics and Policy for Pandemics
- Copyright page
- Epigraph
- Contents
- Contributors
- Preface
- Acknowledgements
- 1 Behavioural Economics and Policy for Pandemics
- Part I Evidence from Experiments and Behavioural Insights
- 2 What Have We Learned from Behavioural Economics for the COVID-19 Response?
- 3 Adaptation, COVID-19, and Climate Change
- 4 Risk-Taking, Risk Perception, and Risk Compensation in Times of COVID-19
- 5 A False Sense of Security?
- 6 Preparing for the Next Pandemic
- 7 Human Challenge Trials for Research on COVID-19 and Beyond
- 8 Do the Public Support ‘Hard’ or ‘Soft’ Public Policies?
- 9 One Size Does Not Fit All
- 10 Psychological and Behavioural Aspects of the COVID-19 Pandemic
- 11 Behavioural Science and the Irish COVID-19 Response
- 12 On the Use of Behavioural Science in a Pandemic
- 13 Behavioural Public Health?
- Part II Health Behaviours and Policies during Covid-19
- Index
- References
Summary
Human challenge trials are trials in which volunteers are intentionally exposed to infectious disease-causing organisms for the purpose of testing novel vaccines or treatments, as well as to study the progression of the disease in a controlled environment. The practice of systematically infecting individuals with pathogens of interest has been recorded since the eighteenth century, although in most cases these infections did not meet the ethical standards that are in place today. With the rise of modern research ethics in the 1970s and the wider implementation of these standards by the 1980s, HCTs that have been conducted more recently have been used to safely study a wide variety of pathogens and speed up the development of vaccines for typhoid and cholera. Despite this historical precedent, the idea of conducting an HCT with SARS-CoV-2 (the causative agent of COVID-19) faced ethical and practical challenges, including the lack of any known rescue treatment for the disease and uncertainty around the potential long-term effects that volunteers exposed to the pathogen might someday experience. This chapter presents the research of 1Day sooner around the development of HCTs in the context of the COVID-19 pandemic and discusses how these findings may be relevant to pandemic preparedness efforts in the future.
- Type
- Chapter
- Information
- Behavioural Economics and Policy for PandemicsInsights from Responses to COVID-19, pp. 114 - 125Publisher: Cambridge University PressPrint publication year: 2024
References
Adams-Phipps, J., Toomey, D., Więcek, W., Schmit, V., Wilkinson, J., Scholl, K., et al. (2023). A systematic review of human challenge trial designs and their safety. Clinical Infectious Diseases, 76(4), 609–619.CrossRefGoogle ScholarPubMed
Eyal, N., Lipsitch, M., & Smith, P. G. (2020). Human challenge studies to accelerate coronavirus vaccine licensure. Journal of Infectious Diseases, 221(11), 1752–1756. https://doi.org/10.1093/infdis/jiaa152CrossRefGoogle ScholarPubMed
Jamrozik, E., & Selgelid, M. J. (2021). Human Challenge Studies in Endemic Settings: Ethical and Regulatory Issues. Springer Nature. https://doi.org/10.1007/978-3-030-41480-1CrossRefGoogle Scholar
Jin, C., Gibani, M. M., Moore, M., Juel, H. B., Jones, E., Meiring, J., et al. (2017). Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: A randomised controlled, phase 2b trial. The Lancet, 390(10111), 2472–2480. https://doi.org/10.1016/S0140-6736(17)32149-9CrossRefGoogle ScholarPubMed
Killingley, B., Mann, A., Kalinova, M., Boyers, A., Goonawardane, N., Zhou, J., et al. (2022). Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine, 28, 1031–1041. https://doi.org/10.1038/s41591-022-01780-9.CrossRefGoogle ScholarPubMed
Lynch, H. F., Darton, T., Largent, E., Levy, J., McCormick, F., Ogbogu, U., et al. (2020). Ethical payment to participants in human infection challenge studies, with a focus on SARS-CoV-2: Report and recommendations. Scholarly Paper 3674548. Social Science Research Network. https://doi.org/10.2139/ssrn.3674548CrossRefGoogle Scholar
Lynch, H. F., Darton, T. C., Levy, J., McCormick, F., Ogbogu, U., Payne, R. O., et al. (2021). Promoting ethical payment in human infection challenge studies. The American Journal of Bioethics, 21(3), 11–31. https://doi.org/10.1080/15265161.2020.1854368CrossRefGoogle ScholarPubMed
Manheim, D., Więcek, W., Schmit, V., Morrison, J., & 1Day Sooner Research Team. (2021). Exploring risks of human challenge trials for COVID-19. Risk Analysis, 41(5), 710–720. https://doi.org/10.1111/risa.13726CrossRefGoogle ScholarPubMed
Marsh, A. A., Magalhaes, M., Peeler, M., Rose, S. M., Darton, T. C., Eyal, N., et al. (2022). Characterizing altruistic motivation in potential volunteers for SARS-CoV-2 challenge trials. PLoS ONE, 17(11), e0275823.CrossRefGoogle ScholarPubMed
Nguyen, L. C., Bakerlee, C. W., McKelvey, T. G., Rose, S. M., Norman, A. J., Joseph, N., et al. (2021). Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development. Clinical Infectious Diseases, 72(4), 710–715. https://doi.org/10.1093/cid/ciaa935CrossRefGoogle ScholarPubMed
Risk Model for Human Challenge Trials. (2021). https://1daysooner.shinyapps.io/Riskmodel/Google Scholar
Rosenheck, M. (2022). Risk, benefit, and social value in Covid-19 human challenge studies: Pandemic decision making in historical context. Monash Bioethics Review, 40(2), 188–213. https://doi.org/10.1007/s40592-022-00156-6.CrossRefGoogle ScholarPubMed
Shah, S., Kimmelman, J., Drapkin Lyerly, A., Fernandez Lynch, H., McCutchan, F., Miller, F., et al. (2017). Ethical considerations for Zika virus human challenge trials: Report & recommendations. www.niaid.nih.gov/sites/default/files/EthicsZikaHumanChallengeStudiesReport2017.pdfGoogle Scholar
Sulmasy, D. P. (2021). Are SARS-CoV-2 human challenge trials ethical? JAMA Internal Medicine, 181(8), 1031–1032. https://doi.org/10.1001/jamainternmed.2021.2614CrossRefGoogle ScholarPubMed
Tacket, C. O., Cohen, M. B., Wasserman, S. S., Losonsky, G., Livio, S., Kotloff, K., et al. (1999). Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infection and Immunity, 67(12). https://doi.org/10.1128/IAI.67.12.6341-6345.1999CrossRefGoogle ScholarPubMed
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., et al. (2020). Factors associated with COVID-19-related death using OpenSAFELY. Nature, 584(7821), 430–436. https://doi.org/10.1038/s41586-020-2521-4CrossRefGoogle ScholarPubMed
World Health Organization. (2020a). Key criteria for the ethical acceptability of COVID-19 human challenge studies. https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdfGoogle Scholar
World Health Organization. (2020b). Feasibility, potential value and limitations of establishing a closely monitored challenge model of experimental COVID-19 infection and illness in healthy young adult volunteers. www.who.int/publications/m/item/feasibility-potential-value-and-limitations-of-establishing-a-closely-monitored-challenge-model-of-experimental-covid-19-infection-and-illness-in-healthy-young-adult-volunteersGoogle Scholar
World Medical Association. (2013). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA, 310(20), 2191–2194. https://doi.org/10.1001/jama.2013.281053CrossRefGoogle Scholar